Kristen Williams - Mar 21, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Administrative Officer
Signature
/s/ Kristen Williams
Stock symbol
PCRX
Transactions as of
Mar 21, 2022
Transactions value $
-$217,613
Form type
4
Date filed
3/23/2022, 04:37 PM
Previous filing
Mar 1, 2022
Next filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $113K +2.95K +13.26% $38.35 25.2K Mar 21, 2022 Direct F1
transaction PCRX Common Stock Options Exercise $92K +2.11K +8.37% $43.54 27.3K Mar 21, 2022 Direct F1
transaction PCRX Common Stock Options Exercise $104K +2.19K +8% $47.65 29.5K Mar 21, 2022 Direct F1
transaction PCRX Common Stock Sale -$527K -7.25K -24.57% $72.67 22.3K Mar 21, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2.95K -50% $0.00 2.95K Mar 21, 2022 Common Stock 2.95K $38.35 Direct F2
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2.11K -16.67% $0.00 10.6K Mar 21, 2022 Common Stock 2.11K $43.54 Direct F2
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2.19K -10% $0.00 19.7K Mar 21, 2022 Common Stock 2.19K $47.65 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.